Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

122.82USD
1:37am IST
Change (% chg)

$0.34 (+0.28%)
Prev Close
$122.48
Open
$121.60
Day's High
$123.32
Day's Low
$121.60
Volume
862,122
Avg. Vol
1,342,714
52-wk High
$123.32
52-wk Low
$74.52

Latest Key Developments (Source: Significant Developments)

Cipla Gets Final Nod For Generic Version Of Eli Lilly & Co.'s Adcirca
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Cipla Ltd ::SAYS RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ELI LILLY & CO.'S ADCIRCA.SAYS PRODUCT IS AVAILABLE FOR SHIPPING IMMEDIATELY.  Full Article

Lilly Announces Top-Line Phase 3 Results For Baricitinib In Patients With Moderate To Severe Atopic Dermatitis
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Eli Lilly and Co and Incyte Corp ::LILLY ANNOUNCES TOP-LINE PHASE 3 RESULTS FOR BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.INCYTE CORP - BARICITINIB MET PRIMARY ENDPOINT IN BREEZE-AD1 AND BREEZE-AD2.INCYTE - IN BOTH INVESTIGATIONAL TRIALS STATISTICALLY SIGNIFICANT PROPORTION OF PATIENTS TREATED WITH BARICITINIB ACHIEVED PRIMARY ENDPOINT AT WEEK 16.INCYTE - SERIOUS ADVERSE EVENTS WITH BARICITINIB TREATMENT WAS SIMILAR TO PLACEBO.  Full Article

Lilly And Loxo Oncology Announce Expiration Of Hart-Scott-Rodino Act Waiting Period
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Loxo Oncology Inc ::LILLY AND LOXO ONCOLOGY ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO ACT WAITING PERIOD IN CONNECTION WITH PROPOSED TRANSACTION.LILLY AND LOXO ONCOLOGY ANNOUNCE EXPIRATION OF HART-SCOTT-RODINO ACT WAITING PERIOD IN CONNECTION WITH PROPOSED TRANSACTION.  Full Article

111 Inc To Collaborate With Lilly For New Solutions For Pharmaceutical Distribution
Monday, 28 Jan 2019 

Jan 28 (Reuters) - 111 Inc ::111, INC. TO COLLABORATE WITH LILLY IN CREATING NEW SOLUTIONS FOR PHARMACEUTICAL DISTRIBUTION.111 INC - CO, ELI LILLY WILL ALSO JOINTLY-DEVELOP INNOVATIVE ONLINE MEDICAL INSURANCE AND PHARMACY BENEFIT MANAGEMENT MODELS.111 INC - TO ROLL OUT "FOURTH SALES CHANNEL" SOLUTION FOR PHARMACEUTICAL COS BY FOCUSING ON BIG DATA, E-PRESCRIPTIONS, DOCTOR SERVICES, PATIENT EDUCATION.111 INC - CO WILL SERVE AS LILLY'S DESIGNATED E-PRESCRIPTION PLATFORM.  Full Article

EMA Says No New Patients Should Start Treatment With Lilly's Lartruvo
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Eli Lilly and Co ::EUROPEAN MEDICINES AGENCY - NO NEW PATIENTS SHOULD START TREATMENT WITH LILLY'S LARTRUVO AFTER STUDY SHOWS CANCER MEDICINE DOES NOT PROLONG LIFE.  Full Article

Lilly Phase 3 Trial Data Published In The Lancet Oncology Shows Improvement In Overall Survival With Cyramza
Saturday, 19 Jan 2019 

Jan 18 (Reuters) - Eli Lilly and Co ::LILLY PHASE 3 REACH-2 TRIAL DATA PUBLISHED IN THE LANCET ONCOLOGY SHOWS IMPROVEMENT IN OVERALL SURVIVAL WITH CYRAMZA® (RAMUCIRUMAB) IN SECOND-LINE AFP-HIGH HEPATOCELLULAR CARCINOMA PATIENTS.REACH-2 SHOWED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT OF OVERALL SURVIVAL.ELI LILLY - SAFETY PROFILE OBSERVED IN REACH-2 STUDY CONSISTENT WITH WHAT HAS BEEN PREVIOUSLY OBSERVED FOR SINGLE-AGENT CYRAMZA IN PATIENTS WITH HCC.ON PRIMARY ENDPOINT OF OS, TREATMENT WITH CYRAMZA SIGNIFICANTLY IMPROVED OS OF PATIENTS COMPARED TO PLACEBO.  Full Article

Lilly Endowment Inc Reports Open Market Sale Of 136,577 Shares Of Eli Lilly's Common Stock
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Eli Lilly and Co ::LILLY ENDOWMENT INC REPORTS OPEN MARKET SALE OF 136,577 SHARES OF ELI LILLY'S COMMON STOCK ON JAN 17 IN MULTIPLE TRANSACTIONS – SEC FILING.LILLY ENDOWMENT INC SAYS OPEN MARKET SALE OF SHARES OF ELI LILLY'S COMMON STOCK IN A PRICE RANGE BETWEEN $117.60 PER SHARE AND $119.13 PER SHARE.  Full Article

Ablexis Announces Expansion Of Non-Exclusive Perpetual License Agreement With Eli Lilly And Company
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Eli Lilly and Co ::ABLEXIS ANNOUNCES EXPANSION OF NON-EXCLUSIVE PERPETUAL LICENSE AGREEMENT WITH ELI LILLY AND COMPANY.ABLEXIS SAYS EXPANDED RIGHTS ENABLE BROADER USE OF ALIVAMAB MOUSE PLATFORM.ABLEXIS SAYS FINANCIAL TERMS OF AGREEMENT INCLUDE AN UNDISCLOSED UPFRONT PAYMENT FROM ELI LILLY.ABLEXIS SAYS ANY POTENTIAL MILESTONES AND ROYALTIES ON PRODUCT SALES WOULD BE PAID BY SUB-LICENSEES OF ALIVAMAB MOUSE PLATFORM..  Full Article

Lilly Endowment Inc Reports Open Market Sale Of 51,766 Shares Of Eli Lilly's Common Stock On Jan 15
Thursday, 17 Jan 2019 

Jan 16 (Reuters) - :LILLY ENDOWMENT INC REPORTS OPEN MARKET SALE OF 51,766 SHARES OF ELI LILLY'S COMMON STOCK ON JAN 15 AT AVERAGE PRICE OF $117.74/SHARE – SEC FILING.  Full Article

Bayer Sees No Impact Of Lilly Deal On Own Partnership With Loxo
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Bayer says on Loxo, Lilly deal::We can't comment on M&A activities of other companies.We don't see an impact to our contract with Loxo Oncology for the time being.  Full Article

Photo

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.